发布文献求助

小马哥

Lv62

1854 积分 2022-12-14 加入

最近求助
最近应助
互助留言

SACITUZUMAB TIRUMOTECAN MONOTHERAPY IN ADVANCED/METASTATIC ENDOMETRIAL CARCINOMA: RESULTS FROM A PHASE 1/2 STUDY (2870-001/KL264-01) 14天前 已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China 20天前 已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China 20天前 已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 20天前 已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 20天前 已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 21天前 已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 21天前 已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China 1个月前 已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 1个月前 已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives 2个月前 已完结

没有进行任何应助

没有进行任何互助留言

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通